Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023

  • DIACC3010 displays broad efficacy in ER+ HER2- breast cancer models.
  • DIACC3010 was evaluated alone and in combination with multiple standards of care, including the 1st FDA-approved oral SERD[1] elacestrant
  • Phase I correlative analyses reveal DIACC3010 and endocrine therapy induce favorable clinical outcome in refractory breast cancer patients bearing ESR1 mutated tumors

DIACCURATE, a late clinical stage precision oncology biopharmaceutical company developing highly differentiated treatments, today announced that it has been selected to present new nonclinical efficacy and clinical exploratory correlative analyses of its lead compound DIACC3010 in metastatic ER+ HER2- breast cancer in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

  • Abstract titleDIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER-positive HER2-negative metastatic breast cancer.
  • Session title: Molecular Targeted Therapies 2
  • Abstract number: 4477
  • Session Date and Time: April 18, 2023 - 9:00 AM to 12:30 PM

The communication features an exploratory correlative analysis from DIACC3010 Phase 1 study focused on the combination cohort of DIACC3010 and tamoxifen, in highly refractory ER+ HER2- metastatic breast cancer patients. The patients who had detectable mutations in the ESR1 gene achieved median progression-free survival of 5.6 months, as compared to only 2.6 months in patients with no detectable ESR1 mutations. In addition, nonclinical efficacy results of DIACC3010 in combination with the SERM tamoxifen and the SERD elacestrant were performed. Combinations of DIACC3010 with CDK4/6 inhibitors such as palbociclib and abemaciclib, in various mouse models of ER+ HER2- breast cancer, will also be disclosed.

Dr Elsa Borghi, MD, PhD, Chief Medical Officer of Diaccurate, commented: “We are thrilled to present this remarkable set of nonclinical and clinical results that converge to support further development of DIACC3010 in ESR1-mutated ER+ HER2- metastatic breast cancer. With these data, Diaccurate is in a position to advance rapidly the development of DIACC3010 through the implementation of a pivotal study in this population of patients with high unmet medical need”.


[1] A selective Estrogen Receptor Degrader or Downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated.